JN.1 and the ongoing battle: unpacking the characteristics of a new dominant COVID-19 variant

References

• Altamimi I, Alabdulkarim IM, Alhumimidi AS, et al. Navigating Novel Uncertainties of COVID-19: The Rise of the JN.1 Variant. Cureus. 2024;16(1):e51497. doi: 10.7759/cureus.51497
   PubMed Web of Science ®Google Scholar
• Yameny AA. Short Communication: The COVID-19 JN.1 variant diagnosed in Egypt. J Med Life Sci. 2023;5(4):318–321. doi: 10.21608/jmals.2024.333814
   Google Scholar
• Khan K, Lustig G, Römer C, et al. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. Nat Commun. 2023;14(1):8078. doi: 10.1038/s41467-023-43703-3
   PubMed Web of Science ®Google Scholar
• Khan SA, Bhuiyan MA, Dewan SMR. JN.1: The Present Public Health Concern Pertains to the Emergence of a Novel Variant of COVID-19. Environ Health Insights. 2024;18:11786302241228958. doi: 10.1177/11786302241228958
   Web of Science ®Google Scholar
• Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2024;24(2): e70–e2. doi: 10.1016/S1473-3099(23)00744-2
   PubMed Web of Science ®Google Scholar
• Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC. Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC. [2023 Dec 8]. Available from: https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html
   Google Scholar
• Yue C, Song W, Wang L, et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23(3):278–280. doi: 10.1016/S1473-3099(23)00010-5
   PubMed Web of Science ®Google Scholar
• Uriu K, Ito J, Zahradnik J, et al. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect Dis. 2023;23(3):280–281. doi: 10.1016/S1473-3099(23)00051-8
   PubMed Web of Science ®Google Scholar
• Satapathy P, Kumar P, Gupta JK, et al. The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health. Int J Surg. 2024;110(4):2498–2501. doi: 10.1097/JS9.0000000000001070
   PubMed Web of Science ®Google Scholar
• ECDC. SARS-CoV-2 variants of concern as of 19 January. 2024.
   Google Scholar
• Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect Dis. 2024 Feb;24(2): e82. doi: 10.1016/S1473-3099(23)00813-7
   PubMed Web of Science ®Google Scholar
• Chakraborty A. Higher Omicron JN.1 Coronavirus Transmission due to Unique 17MPLF Spike Insertion compensating 24LPP, 69HV, 145Y, 211N and 483V deletions in the spike. 2024.
   Google Scholar
• Chakraborty A. The G36S, M147I, G265S, T568I, N852S new mutations in the Spike of Omicron JN.1 subvariants: New subvariants JN.1.1 to JN.1.5 nomenclature and oligonucleotides design for JN.1 subvariants detection. 2024.
   Google Scholar
• Popović ME, Stevanović M, Mihailović M. Breaking news: Empirical formulas, molar masses, biosynthesis reactions, and thermodynamic properties of virus particles, biosynthesis and binding of Omicron JN. 1 variant of SARS-CoV-2. J Serb Chem Soc. 2024;2024(3):19–19. doi: 10.2298/JSC240119019P
   Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162–177. doi: 10.1038/s41579-022-00841-7
   PubMed Web of Science ®Google Scholar
• Chalkias S, McGhee N, Whatley JL, et al. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines. J Infect Dis. 2024:jiae067. doi: 10.1093/infdis/jiae067
   PubMedGoogle Scholar
• Wang Q, Guo Y, Bowen A, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024 Mar 13;32(3): 315–321.e3. doi: 10.1016/j.chom.2024.01.014
   PubMed Web of Science ®Google Scholar
• Tortorici MA, Addetia A, Seo AJ, et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity. 2024 Apr 9;57(4): 904–911. doi: 10.1016/j.immuni.2024.02.016
   PubMed Web of Science ®Google Scholar
• Fan H, Qin S, Cui Y. Emergence and Characterization of the SARS-CoV-2 JN. 1 Variant: Global Prevalence and Implications for Public Health. Zoonoses. 2024;4(1):994. doi: 10.15212/ZOONOSES-2023-0061
   Google Scholar
• Morusupalli R, Vijaykumar Chennamchetty D, Pavani G, et al. Understanding the Molecular Basis of Jn.1. Int Educ Res. 2024;10(1):36–40. doi: 10.21276/IERJ24815318066840
   Google Scholar
• Quarleri J, Delpino MV, Galvan V. Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN.1 and its projected impact on older adults. Geroscience. 2024;46(3):2879–2883. doi: 10.1007/s11357-024-01066-7
   PubMedGoogle Scholar
• Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA. 2.86 to JN. 1 under heavy immune pressure. Lancet Infect Dis. 2024;24(2):e70–e72. doi: 10.1016/S1473-3099(23)00744-2
   PubMed Web of Science ®Google Scholar
• Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the SARS-CoV-2 JN. 1 variant. Lancet Infect Dis. 2024;24(2):e82. doi: 10.1016/S1473-3099(23)00813-7
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Coyle P, Ben Kacem MA, et al. Protection of natural infection against reinfection with SARS-CoV-2 JN. 1 variant. medRxiv. 2024;31(4):2024.02. 22.24303193. doi: 10.1093/jtm/taae053
   Google Scholar
• World Health Organization. Statement on the antigen composition of COVID-19 vaccines. 2023 Dec 13. Available from: https://www.who.int/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines
   Google Scholar
• Li P, Liu Y, Faraone JN, et al. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. mBio. 2024 May 8;15(5):e0075124. doi: 10.1128/mbio.00751-24
   PubMed Web of Science ®Google Scholar
• Lambrou AS, South E, Ballou ES. Early detection and surveillance of the SARS-CoV-2 variant BA. 2.86—worldwide, July–October 2023. MMWR Morb Mortal Wkly Rep. 2023;72(43):1162–1167. doi: 10.15585/mmwr.mm7243a2
   PubMed Web of Science ®Google Scholar
• McManus O, Christiansen LE, Nauta M, et al. Predicting COVID-19 Incidence Using Wastewater Surveillance Data, Denmark, October 2021–June 2022. Emerg Infect Dis. 2023;29(8):1589–1597. doi: 10.3201/eid2908.221634
   PubMed Web of Science ®Google Scholar
• Espinosa-Gongora C, Berg C, Rehn M, et al. Early detection of the emerging SARS-CoV-2 BA.2.86 lineage through integrated genomic surveillance of wastewater and COVID-19 cases in Sweden, weeks 31 to 38 2023. Eurosurveillance. 2023;28(46):28. doi: 10.2807/1560-7917.ES.2023.28.46.2300595
   Web of Science ®Google Scholar
• Karthikeyan S, Levy JI, De Hoff P, et al. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature. 2022;609(7925):101–108. doi: 10.1038/s41586-022-05049-6
   PubMed Web of Science ®Google Scholar
• Bartel A, Grau JH, Bitzegeio J, et al. Timely Monitoring of SARS-CoV-2 RNA Fragments in Wastewater Shows the Emergence of JN.1 (BA.2.86.1.1, Clade 23I) in Berlin, Germany. Viruses. 2024;16(1):1. doi: 10.3390/v16010102
   Web of Science ®Google Scholar